APHA Compound 8 – 1 mg

Brand:
Cayman
CAS:
676599-90-9
Storage:
-20
UN-No:
Non-Hazardous - /

APHA compound 8 is an inhibitor of class I histone deacetylases (HDACs; IC50s = 3.7, 7.4, 0.42, and 2.8 μM for HDAC1, -2, -3, and -8, respectively) as well as class II HDACs (IC50s = 3.1, 0.1, 3.1, and 4.2 μM for HDAC4, -6, -7, and -10, respectively).{46978} It is selective for class I and II HDACs over class III HDACs (IC50s = >30 μM for SIRT1, SIRT2, and SIRT3) and the histone acetyltransferase PCAF (IC50 = >30 μM). At 48 hours post-infection, APHA compound 8 increases replication of oncolytic herpes simplex virus (oHSV) in MDA-MB-231 and 4T1 breast cancer cells when used prior to viral infection at concentrations of 10 and 50 μM.{46979}  

 

Out of stock

SKU: 21228 - Category:

Description

A class I (IC50s = 3.7, 7.4, 0.42, and 2.8 μM for HDAC1, -2, -3, and -8, respectively) and class II HDAC inhibitor (IC50s = 3.1, 0.1, 3.1, and 4.2 μM for HDAC4, -6, -7, and -10, respectively); selective for class I and II HDACs over class III HDACs (IC50s = >30 μM for SIRT1, SIRT2, and SIRT3) and the histone acetyltransferase PCAF (IC50 = >30 μM); at 48 hours post-infection, increases replication of oHSV in MDA-MB-231 and 4T1 breast cancer cells at 10 and 50 μM prior to viral infection


Formal name: N-hydroxy-3-[1-methyl-4-(2-phenylacetyl)-1H-pyrrol-2-yl]-2-propenamide

Synonyms:  MC 1353

Molecular weight: 284.3

CAS: 676599-90-9

Purity: ≥98%

Formulation: A solid


Product Type|Biochemicals|Small Molecule Inhibitors|Deacetylases||Research Area|Cancer||Research Area|Epigenetics, Transcription, & Translation|Erasers|Histone Deacetylation